Inhibikase Therapeutics Ownership
| IKT Stock | USD 2.37 0.05 2.07% |
Shares in Circulation | First Issued 2019-03-31 | Previous Quarter 7.5 M | Current Value 8.9 M | Avarage Shares Outstanding 3.7 M | Quarterly Volatility 2.3 M |
Inhibikase |
Inhibikase Stock Ownership Analysis
About 12.0% of the company shares are held by company insiders. The company recorded a loss per share of 3.12. Inhibikase Therapeutics had not issued any dividends in recent years. The entity had 1:6 split on the 30th of June 2023. Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinsons Disease and related disorders that arise inside and outside of the brain. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia. Inhibikase Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 6 people. To learn more about Inhibikase Therapeutics call the company at 678 392 3419 or check out https://www.inhibikase.com.Besides selling stocks to institutional investors, Inhibikase Therapeutics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Inhibikase Therapeutics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Inhibikase Therapeutics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Inhibikase Therapeutics Quarterly Liabilities And Stockholders Equity |
|
Inhibikase Therapeutics Insider Trades History
About 12.0% of Inhibikase Therapeutics are currently held by insiders. Unlike Inhibikase Therapeutics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Inhibikase Therapeutics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Inhibikase Therapeutics' insider trades
Inhibikase Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Inhibikase Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Inhibikase Therapeutics backward and forwards among themselves. Inhibikase Therapeutics' institutional investor refers to the entity that pools money to purchase Inhibikase Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Geode Capital Management, Llc | 2024-12-31 | 322.9 K | Millennium Management Llc | 2024-12-31 | 142.2 K | Blair William & Co | 2024-12-31 | 135 K | Barclays Plc | 2024-12-31 | 84 K | Citigroup Inc | 2024-12-31 | 77.1 K | Northern Trust Corp | 2024-12-31 | 64 K | Omers Administration Corp | 2024-12-31 | 54.6 K | Hrt Financial Llc | 2024-12-31 | 46.4 K | Goldman Sachs Group Inc | 2024-12-31 | 44 K | Sands Capital Ventures, Llc | 2024-12-31 | 10.9 M | Soleus Capital Management, L.p. | 2024-12-31 | 6.3 M |
Inhibikase Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Inhibikase Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Inhibikase Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Inhibikase Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Inhibikase Therapeutics Outstanding Bonds
Inhibikase Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Inhibikase Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Inhibikase bonds can be classified according to their maturity, which is the date when Inhibikase Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| INGREDION INC 32 Corp BondUS457187AB87 | View | |
| US457187AC60 Corp BondUS457187AC60 | View | |
| US457187AD44 Corp BondUS457187AD44 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Inhibikase Therapeutics Corporate Filings
F3 | 25th of February 2025 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
8K | 24th of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 19th of February 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 14th of February 2025 Other Reports | ViewVerify |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Inhibikase Stock Analysis
When running Inhibikase Therapeutics' price analysis, check to measure Inhibikase Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inhibikase Therapeutics is operating at the current time. Most of Inhibikase Therapeutics' value examination focuses on studying past and present price action to predict the probability of Inhibikase Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inhibikase Therapeutics' price. Additionally, you may evaluate how the addition of Inhibikase Therapeutics to your portfolios can decrease your overall portfolio volatility.